利用MPTP建立帕金森病动物模型的安全与防护策略

The Safety Strategy of Using MPTP in PD Animal Model

帕金森氏病 (Parkinsondisease,PD)是一种常见的神经系统变性性疾病。该病的主要临床表现为 :静止性震颤、僵硬、动作迟缓和姿势不稳。 1917年英国医学帕金森 (JameParkinson)首先描述了这一临床症状。该病主要由于黑质致密部多巴胺能神经元的减少 ,致使纹状体多巴胺的含量降低所致。近年来 ,研究者利用 6 OHDA(六羟多巴胺 )、MPTP(1 甲基 4 苯基 1,2 ,3,6 四氢吡啶 )等成功建立了帕金森病动物模型 ,对多巴胺能神经元死亡的病因进行了大量的研究 ,但由于MPTP是一种很强的神经毒素 ,在使用过程中极易对研究者造成潜在的影响 ,因此本文对MPTP的安全使用和研究者的自身防护进行了探讨。

Parkinson's disease(PD) is a common disabling meurodegenertive disorder the cardinal features of which include tremor, rigidity and slowness of movement. In 1817, Jame Parkinson first described the disorder. This disorder is attributed mainly to a profound reduction of dopamine in the striatum due to dramatic loss of dopminergic neurous in the substantra nigra pars compacta(SNpc). Over the years, investigators have used experimental models of PD produced by 6-hydroxydopamine(6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydoyndine(MPTP) to provide insights into the mechamisms responsible for the demice of dopaminergic neurous in PD. Humans are the most vulnerable to this neurotoxin. So it is important to inform the researcher of the hazardous nature of MPTP and to prvide guidance for its safe handing and use.